Should you buy Filana Therapeutics stock now?
No, the technical signal for Filana Therapeutics is currently SELL. Filana Therapeutics trades at $0.96 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.065 with rising momentum (signal: -0.077); RSI is at 39.7 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $6.50 points to 577.2% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Filana Therapeutics stock?
The average analyst price target for Filana Therapeutics is $6.50. The current price is $0.96, which gives an upside of 577.2%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $5.85 and $7.15.
Is Filana Therapeutics a dividend stock?
No, Filana Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Filana Therapeutics stock?
Filana Therapeutics is rated as a stock with extreme risk. the annual standard deviation is 90.1%, which classifies the stock as extreme risk.
Is Filana Therapeutics overvalued?
No, Filana Therapeutics is considered undervalued based on the analyst price target (577.2% upside). Filana Therapeutics has the following valuation ratios: a P/S ratio of 2.5, a P/B ratio of 0.8. The analyst price target suggests that the stock is undervalued by 577.2%.
Is Filana Therapeutics overbought?
No, Filana Therapeutics is not overbought. RSI is at 39.7 (neutral zone). The technical indicators show: RSI is at 39.7 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 5.3% below the 20-day average (short-term downtrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Filana Therapeutics earnings report?
The date of the next earnings report for Filana Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Filana Therapeutics shorted?
Yes, Filana Therapeutics is shorted with 13.2% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Filana Therapeutics stock?
Yes, insiders are net buyers of Filana Therapeutics – they are buying more shares than they are selling. Across the last 7 reported transactions, the split is 5 purchases and 2 sales, with a net 547,146 $ bought. Active buyers include Richard Barry, Robert Christopher Cook. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Filana Therapeutics a good stock?
Based on our total score, Filana Therapeutics is rated as a poor stock with a total score of 20 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 43/100, Quality: 16/100, Momentum: 2/100. In addition: analysts see 577.2% upside to the price target; technical signal: Strong Sell. Whether Filana Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Filana Therapeutics stock?
The outlook for Filana Therapeutics based on current data: the average analyst price target is $6.50 (+577.2%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Filana Therapeutics stock falling?
Filana Therapeutics is falling right now. The technical indicators show: the price is 5.3% below the 20-day average; short interest is 13.2% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Filana Therapeutics go?
The average analyst price target for Filana Therapeutics is $6.50, which corresponds to a potential gain of 577.2% from the current price of $0.96. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Filana Therapeutics fall?
We lack enough history to give a specific floor for Filana Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Filana Therapeutics do?
Cassava Sciences er et biotekfirma, der udvikler medicin mod neurologiske sygdomme. De fokuserer især på at finde nye behandlinger for lidelser som Alzheimers. Deres hovedprodukt, Simufilam, er et lægemiddel, der lige har afsluttet Fase 2b forsøg. Derudover laver de et diagnos... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Filana Therapeutics as an investment.
Did Filana Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Filana Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Filana Therapeutics making money or losing money?
We have no current profitability data for Filana Therapeutics. See the latest report in the earnings history above.
Can Filana Therapeutics go bankrupt?
The bankruptcy risk of Filana Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -14.54 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 8% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Filana Therapeutics have a lot of debt?
No, Filana Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 8%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
